Business
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027 Expanded Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader Antibody Conjugates Cas
About this update from C4 Therapeutics, Inc.
[{"type":"image","alt":"C4 Therapeutics, Inc.","displaySize":"","headline":null,"caption":"C4 Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3E2kpCmCaMpi6X3wXPV0rA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85","width":300,"height":45},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/3E2kpCmCaMpi6X3wXPV0rA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/bde91dc9d9165d239ff6e430c73a2d85","width":300,"height":45}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:100%;width:100%;min-width:100%;text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab","length":199,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Additional Phase 1b Trial Evaluating Cemsidomide in Combination with Approved Multiple Myeloma Therapies Expected to Initiate in the First Half of 2027","length":151,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bottom;","val":[{"type":"text","content":"Expanded Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader Antibody Conjugates","length":144,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:center;vertical-align:middle;padding-left:0;padding-right:0;vertical-align:bo...